No Data
No Data
Why Cytokinetics Stock Was a Nearly 5% Winner Today
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China
Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi